Paratek Pharmaceuticals has recently finalized the acquisition of Optinose, a deal valued at nearly $330 million. This strategic move has significantly expanded Paratek’s commercial product offerings, solidifying its position in the pharmaceutical market.
The merger agreement between the two companies was officially signed in March 2025, paving the way for a comprehensive consolidation of their respective portfolios. Paratek’s lineup now includes its flagship antibiotic, Nuzyra (omadacycline), as well as Optinose’s Xhance (fluticasone propionate), a key addition to their product range.
The acquisition encompasses all outstanding shares of Optinose, including debt assumption and full payment of contingent value rights (CVRs). Shareholders of Optinose gave their approval for the merger on 16 May, marking a significant milestone in the consolidation process. Capital for the transaction was provided by Paratek, Novo Holdings, and B-FLEXION Life Sciences, with additional debt financing from Oaktree Capital Management funds.
Under the terms of the agreement, Optinose shareholders received $9 per share in cash and CVRs worth up to $5 per share, contingent upon Xhance achieving specific net revenue milestones. Paratek has committed to paying $1 per share upon Xhance reaching $150 million in net sales in any calendar year before 31 December 2028, and an extra $4 per share if the sales hit $225 million before 31 December 2029.
Nuzyra, Paratek’s leading antibiotic, is designed to combat tetracycline resistance and is effective against a wide range of bacteria, including drug-resistant strains. It is available in both oral and intravenous formulations for the treatment of community-acquired bacterial pneumonia and acute bacterial skin infections. On the other hand, Xhance, a drug-device combination product from Optinose, utilizes the exhalation delivery system to deliver the topical steroid to the deep nasal cavity areas.
CEO of Paratek Pharmaceuticals, Evan Loh, expressed his excitement about the acquisition, stating that adding Xhance to their portfolio is a significant step towards achieving their long-term goal of becoming a multi-product specialty therapeutics company. He emphasized the importance of addressing unmet medical needs and leveraging their capabilities to explore future opportunities for portfolio expansion through additional product acquisitions.
Lazard and Skadden, Arps, Slate, and Meagher & Flom provided exclusive financial and legal advisory services to Paratek during the acquisition process, while Evercore and Hogan Lovells US assisted Optinose. The successful integration of Optinose into Paratek’s commercial portfolio marks a new chapter for the company, setting the stage for continued growth and innovation in the pharmaceutical industry.
The article “Paratek expands commercial portfolio with Optinose” was originally published by Pharmaceutical Technology, a GlobalData-owned brand, providing valuable insights into the latest developments in the healthcare sector.
